U.S. clinical testing of Theseus Imaging's Hynic-Annexin V molecular imaging agent appears set to resume. The firm is planning phase II studies in the U.S. to assess the predictive value of the radiopharmaceutical at various times following a single course of chemotherapy, according to Theseus parent North American Scientific of Chatsworth, CA.
The clinical study is designed to provide information about product safety, biodistribution, and imaging technique after chemotherapy in non-small cell lung cancer patients, NAS said. The firm's investigational new drug (IND) application was opened May 9 after Theseus had responded to comments from the Food and Drug Administration. Theseus had pulled its initial IND application in January.
By AuntMinnie.com staff writersJune 13, 2003
Related Reading
NAS sales sag in Q2, May 22, 2003
NAS resubmits IND, May 9, 2003
NAS shows sales uptick, February 25, 2003
Theseus in co-development deal with NCI, February 18, 2003
Theseus withdraws IND application, January 21, 2003
Copyright © 2003 AuntMinnie.com
